First National Bank of Omaha’s Genomic Health, Inc. GHDX Stock Holding History

First National Bank of Omaha’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-30,105	Closed	-$1.03M	–	395
2017 Q4	$1.03M	Buy	30,105 +4,425	+17%	+$141K	0.06%	282
2017 Q3	$824K	Buy	25,680 +350	+1%	+$11K	0.05%	291
2017 Q2	$824K	Sell	25,330 -410	-2%	-$13K	0.05%	290
2017 Q1	$811K	Buy	25,740 +4,553	+21%	+$135K	0.05%	299
2016 Q4	$623K	Buy	21,187 +122	+0.6%	+$3.72K	0.04%	308
2016 Q3	$609K	Buy	21,065 +2,340	+12%	+$65.2K	0.04%	251
2016 Q2	$485K	Buy	18,725 +25	+0.1%	+$664	0.04%	252
2016 Q1	$463K	Sell	18,700 -1,085	-5%	-$29.8K	0.03%	268
2015 Q4	$696	Sell	19,785 -4,565	-19%	-$122K	0.05%	224
2015 Q3	$515	Buy	24,350 +7,625	+46%	+$196K	0.04%	255
2015 Q2	$453	Hold	16,725	–	–	0.03%	296
2015 Q1	$453	Buy	16,725 +805	+5%	+$25.6K	0.03%	296
2014 Q4	$509K	Buy	15,920 +3,245	+26%	+$106K	0.04%	290
2014 Q3	$359K	Hold	12,675	–	–	0.03%	321
2014 Q2	$347K	Buy	+12,675	New	+$337K	0.02%	338

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

First National Bank of Omaha's GHDX Position: Q1 2018 in Review

First National Bank of Omaha sold out of Genomic Health, Inc. (GHDX) in Q1 2018, closing a stake of 30,105 shares — an estimated $1.03M sold.

First National Bank of Omaha first reported a position in GHDX in Q2 2014 and held it in 15 quarters. The position peaked at $1.03M in Q4 2017. 134 funds tracked by Wall St. Rank hold GHDX as of Q1 2018.

First National Bank of Omaha reported no remaining Genomic Health, Inc. position as of Q1 2018 after selling out during the quarter.
First National Bank of Omaha sold 30,105 Genomic Health, Inc. shares in Q1 2018, an estimated $1.03M.
First National Bank of Omaha first reported a position in Genomic Health, Inc. in Q2 2014 and held it in 15 quarters.
First National Bank of Omaha's Genomic Health, Inc. position peaked at $1.03M in Q4 2017.
134 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2018.

Based on First National Bank of Omaha's 13F filing for Q1 2018, filed 3 May 2018.